Please assess the completion status of the following clinical trial:

Trial Title: FLX475 in Combination With Ipilimumab in Advanced Melanoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Stage IV or unresectable Stage III advanced melanoma~* Prior treatment with at least 2 months of anti-PD-(L)1 agent~* Measurable disease at baseline~* Tumor available for biopsy~Exclusion Criteria:~* History of allergy or severe hypersensitivity to biologic agents~* History of Grade 3-4 immune-related adverse events leading to discontinuation of prior immunotherapy~* Prior treatment with ipilimumab or other (cytotoxic T-lymphocyte-associated antigen 4) CTLA-4 antagonists

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- FLX475 and ipilimumab combination therapy (Type: EXPERIMENTAL): Participants received FLX475 tablets orally and ipilimumab by IV infusions

Based on this trial design, predict the completion outcome and termination type (if applicable).